Serum levels and in vitro production of Th1- and Th2-type cytokines by peripheral blood mononuclear cells in patients suffering from systemic lupus erythematosus

Journal of Medical Biochemistry

Volumn 29, Issue 1, 2010, Pages 19-27

  Dordević, Vidosava ^a   Zvezdanović, Lilika ^b   Ćosić, Vladan ^b   Vlahović, Predrag ^b   Kundalić, Slavica ^b   Jevtović Stoimenov, Tatjana ^a   Stamenković, Bojana ^c   Mitrović, Dragoslav ^d  

^a Institute of Biochemistry   (Serbia)

^b Clinical Center   (Serbia)

^c Institute for Cardiovascular and Rheumatic Diseases   (Serbia)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Adhesion molecules; Adhezioni molekuli; Con A; In vitro production; In vitro produkcija; Lupus vasculitis; PMA; Serum concentrations; Serumske koncentracije; Systemic lupus erythematosus; Th1 Th2 citokini; Th1 Th2 cytokines

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

EID: 77749298281     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-010-0005-z     Document Type: Article

References (53)

1. th ed., Atlanta, GA: Arthritis Foundation, 1988: 96-111.
2. Mok CC, Lau CS. Pathogenesis of systemic lupus ery-thematosus. J Clin Pathol 2003; 56: 481-90.
3. Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH. Recent advances in vascular inflammation: C-reactive proteins and other inflammatory biomarkers. Curr Opin Rheumatol 2004; 16: 18-24.
4. Sundy JS, Haynes B F. Cytokines and adhesion molecules in the pathogenesis of vasculitis. Curr Sci 2000; 2: 402-10.
5. th edition, New York 1994: 1670-9.
6. Rees JD, Lança S, Marques P V, Gomez-Puerta JA, Moco R, Olivieri C, et al. Prevalence of the antiphos-pholipid syndrome in primary systemic vasculitis. Ann Rheumat Dis 2006; 65: 109-11.
7. Miyata M, Ito O, Kobayashi H, Sasajima T, Ohira H, Suzuki S, et al. CpG-DNA derived from sera in systemic lupus erythematosus enhances ICAM-1 expression on endothelial cells. Ann Rheum Dis 2001; 60: 685-9.
8. Paleolog EM, Young S, Stark AC, McCloskey R V, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258-65.
9. Epstein FH. Cytokine pathway and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
10. Topham MK, Carveth HJ, Mc Intyre TM, Prescott SM, Zimmerman GA. Human endothelial cells regulate polymorphonuclear leukocyte degranulation. FASEB J 1998; 12: 9733-46.
11. Tesar V, Masek Z, Rychlik I, Merta M, Bartunkova J, Stejskalova A, et al. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 1998; 13: 1662-7.
12. Ta n EM, Cohen AS, Fries J F, Masi AT, McShane DJ, Rothfield N F, et al. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-17.
13. Hochberg MC. Updating the American College of Rheu matology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997; 40: 1725.
14. Bombardier C, Gludman D, Urowitz M, Caron D, Chang C. Committee on progres studies in SLE. Derivation of SLEDAI. Arthritis Rheum 1992; 35: 630-40.
15. Burger MM, Noonan KD. Restoration of normal growth by covering of agglutinin sites on tumour cell surface. Nature 1970; 228: 512-5.
16. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 1984; 308: 693-8.
17. Al-Janadi M, al-Balla S, al-Dalaan A, Razinddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 1993; 13: 58-67.
18. Jacob C. Tumor necrosis factor α in autoimmunity: pretty girl or witch. Immunol Today 1992; 13: 122-5.
19. Gabav C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303-8.
20. Anderka D, Wysenbeek A, Engelmann H, Cope A P, Brennan F, Molad Y, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1111-20.
21. Lacki JK, Leszczynski P, Kckmen J, Muller W, Mackiewicz SH. Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. J Med 1997; 28: 99-107.
22. Svenungsson E, Andersson M, Brundin L, Van Vollen-hoven R, Khademi M, Tarkowski A, et al. Increa sed levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 2001; 60: 372-9.
23. Lacki JK, Leszczynski P, Keleman J, Müller W, Mackiewicz SH. Cytokine concentration in serum of lupus ery-thematosus patients. J Med 1997; 28: 99-107.
24. Gattorno M, Picco P, Barbano G, Stalla F, Sormani M P, Buoncompagni, A et al. Differences in tumor necrosis-alpha soluble receptor serum concentrations between patients with Henoch-Schönlein purpura and pediatric systemic lupus erythematosus: pathogenetic implications. J Rheumtol 1998; 25: 361-5.
25. Heilig B, Fichen C, Brockhaus M, Gallati H, Pezzutto A, Hustein W. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematosus, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993; 13: 321-8.
26. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNF-alpha, p55 srTNF-alpha, p75 sr TNF-alpha, sr IL-2 alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999; 18: 17-22.
27. Tesar V, Jirsa M, Zima T, Kalousova M, Bartunkovà J, Sejkalovà A, et al. Soluble cytokine receptors in renal vasculitis and lupus nephritis. Med Sci Monit 2002; 8: BR24-9.
28. Robak E, Sysa-Jedrzejewska A, Dziankowska B, Torzecka D, Chojnovski K, Robak T. Association of interferon gamma, tumor necrosis factor alpha and interleukin-1 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp (Warsz)1998; 46: 375-80.
29. Csiszar A, Nagy G, Gergely P, Pozsonyi T, Pocsik E. Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2000; 122: 464-70.
30. Vialard J F, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M, et al. Th1 (IL-2, interferon-gamma (IFN-gamma), and TH2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999; 115: 189-95.
31. Amel-Kashipaz MR, Higgins ML, Lanyon P, Robins A, Todd I, Powell RJ. Quantitative and qualitative analysis of the balance between type 1 and 2 cytokine-producing CD8(-) and CD8(+) T cells in systemic lupus ery-thematosus. J Autoimmun 2001; 17: 155-63.
32. Horwitz DA, Gray JD, Behrendsen SC, Kubin M, Rengaraju M, Ohtsuka K, Trinchieri G. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythe-matosus. Arthritis Rheum 1998; 41: 838-44.
33. Dellalibera-Joviliano R, Dos Reisz ML, Nunha Fde O, Donadi EA. Kinins and cytokines in plasma and cere-brospinal fluid of patients with neuropsychiatric lupus. J Rheumatol 2003; 30: 485-92.
34. Liou LB. Serum and in vitro production of IL-1 receptor antagonists correlates with c-reactive protein levels in newly diagnosed untreated lupus patients. Clin Exp Rheumatol 2001; 19: 515-23.
35. Scuderi F, Convertino R, Molino N, Provenzano C, Marino M, Zoli A, Bartoccioni E. Effect of pro-inflammatory/anti-inflammatory agents on cytokine secretion by peripheral blood mononuclear cells in rheumatoid arthritis and systemic lupus erythematosus. Auto immunity 2003; 36: 71-7.
36. Andersen LS, Petersen J, Svenson M, Bendtzen K. Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE. Autoimmunity 1999; 30: 235-42.
37. Chang DM. Interleukin-1 and Interleukin-1 receptor antagonist in systemic lupus erythematosus. Immunol Invest 1997; 26: 649-59.
38. Suzuki H, Takemura H, Kashiwagi H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity. Arthritis Rheum 1995; 38: 1055-9.
39. Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 1997; 36: 1283-9.
40. Katial RK, Sachanadani D, Pinney C, Lieberman MM. Cytokine production in cell culture by peripheral blood mononuclear cells from immunocompetent hosts. Clin Diagnos Lab Immunol 1998; 5: 78-81.
41. Lorente L, Richaud-Patin Y, Widenes J, Alcocer-Varela J, Maillot MC, Duarand-Gasselin I, et al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993; 4: 421-7.
42. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klare skog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000; 18: 565-70.
43. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1988; 16: 283-8.
44. Lazurova I, Macejova Z, Benhatchi K, Oetterovà M, Antolovà A, Asherson RA, Rovenski J. Efficacy of intravenous immunoglobulin treatment in lupus erythe-matosus chorea. Clin Rheumatol 2007; 26: 2145-7.
45. Horwitz DA, Garrett MA. Lymphocyte reactivity to mitogens in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Clin Exp Immunol 1977; 27: 92-9.
46. Zusen XU, Yanlei C. Determination of serum inter-leukin-13 and nerve growth factor in patients with systemic lupus erythematosus and clinical significance. J Huazhong Univers Sci Technol 2005; 25: 360-1.
47. Spadaro A, Rinaldi T, Riccieri V, Taccari E, Valesini G. Interleukin-13 in autoimmune rheumatic diseases: relationship with the autoantibody profile. Clin Exp Rheumatol 2002; 20: 213-6.
48. Tokano Y, Morimoto S, Kaneko H, Amano H, Nozawa K, Takasaki Y, Hashimoto H. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Th1- and Th2-derived cytokines. Clin Exp Immunol 1999; 116: 169-173.
49. Spadaro A, Scrivo R, Bombardieri M, Riccieri V, Rinaldi T, Taccari E, Valesini G. Relationship of interleukin-12 and interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus. Clin Rheumatol 2003; 22: 107-11.
50. Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythe-matosus. J Clin Invest 1982; 69: 1388-92.
51. Van Pelt J, Romijn P.H.T.M.F. Long-term Quality of the cytokine a growth factors and cell adhesion molecule arrays at the Randox Evidence Investigator. Journal of Medical Biochemistry 2009; 28: 300-304.
52. Kliukvina N, Shekshina S, Alexandrova E, Novicov A, Nassonov E. Elevated levels of soluble intercellular adhesion molecule-1 in systemic lupus erythematosus. 21st European Workshop for Rheumatology Research, Vienna, Austria. Arthritis Res 2001; 3 (Suppl A): A1-47.
53. Ahmad M, Nobuyuki M, Alexander W, Medford R. Cell type-specific transactivation of the VCAM-1 promoter through an NF-κB enhancer motif. J Biol Chem 1995; 270: 8976-83.